Quick Overview: CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and Interview with Christopher Moreau, CEO of Interview with Christopher J. Moreau, CEO of

Algernon Pharmaceuticals Plans Phase 2 - Detailed Overview & Context

CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and Interview with Christopher Moreau, CEO of Interview with Christopher J. Moreau, CEO of

Photo Gallery

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil.
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient
Algernon Pharmaceuticals releases details of Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study
Algernon Pharmaceuticals  (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans
Algernon Pharmaceuticals sees more positive date from Phase 2 study on Ifenprodil for IPF and Cough
Algernon Pharmaceuticals Update - IPF/Chronic Cough Studies
Algernon Pharmaceuticals releases positive data from study on Ifenprodil for IPF and Chronic Cough
Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study
Algernon Pharmaceuticals gets green light from data and safety board to continue Phase 2b-3 study
Algernon Pharmaceuticals receives ok from South Korea for phase two study of Ifenprodil
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored